SCHEDULE: Intracoastal Capital, Kopin, Asher Disclose 9.99% Stake in PharmaCyte

Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher have disclosed a combined beneficial ownership of 9.99% of PharmaCyte Biotech, Inc.'s common stock, as detailed in an amended Schedule 13G filing.

Summary

• Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher collectively reported beneficial ownership of PharmaCyte Biotech, Inc. common stock.
• As of September 30, 2025, Intracoastal Capital and Mr. Kopin each beneficially owned 695,715 shares, representing 9.99% of the common stock.
• This ownership for Intracoastal and Mr. Kopin includes 527,376 shares held directly by Intracoastal and 168,339 shares issuable from Intracoastal Warrant 1.
• As of September 30, 2025, Mr. Asher beneficially owned 686,533 shares, also representing 9.99% of the common stock.
• Mr. Asher's ownership includes 527,376 shares held by Intracoastal, 82,727 shares held directly by Mr. Asher, and 76,430 shares issuable from Intracoastal Warrant 1.
• The reported percentages are calculated based on 6,795,779 shares outstanding as of September 12, 2025, plus exercisable warrants for each reporting person.
• Significant additional shares (over 15 million for each reporting person) are held via warrants and convertible preferred stock but are subject to 'blocker provisions' that prevent beneficial ownership from exceeding 9.99% (or 4.99% for certain instruments) of the outstanding common stock.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. While it's a routine ownership disclosure, the significant stake by Intracoastal Capital and its principals could be viewed as a vote of confidence. However, the large number of unexercised warrants and convertible preferred stock with blocker provisions introduces a potential overhang and complexity to the capital structure, which could be seen as a slight negative.

Positives

• Significant institutional ownership by Intracoastal Capital and its principals, potentially indicating confidence in PharmaCyte Biotech.
• The reporting persons explicitly state that the securities were not acquired for the purpose of changing or influencing control of the issuer, which can reduce concerns about activist investor intentions.

Negatives

• The presence of numerous warrants and convertible preferred stock with blocker provisions suggests a complex capital structure and potential for significant future dilution if these blockers are removed or the ownership thresholds are adjusted.
• The substantial difference between current beneficial ownership (9.99%) and potential ownership without blocker provisions (over 15 million shares) highlights a large overhang of unexercised/unconverted securities.

Risks

• Potential Dilution: The existence of multiple warrants (Intracoastal Warrants 1-5) and Series H Convertible Preferred Stock, which could convert into over 15 million shares without blocker provisions, poses a significant future dilution risk to existing shareholders if these securities are fully exercised or converted.
• Complex Capital Structure: The intricate web of warrants and convertible preferred stock with varying blocker provisions (9.99% and 4.99%) indicates a complex capital structure that may be difficult for investors to fully assess.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure of significant ownership by an institutional investor and its principals in a biotechnology company. Such disclosures are common and provide transparency regarding major shareholders, but do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could be viewed positively, indicating investor interest. However, the large number of unexercised warrants and convertible preferred stock could lead to future dilution, impacting per-share value.

Key Dates

Recommendation

This Schedule 13G filing primarily provides transparency on significant beneficial ownership by Intracoastal Capital and its principals. While a substantial institutional stake can be a positive signal, the filing itself does not contain new operational or financial data to warrant a 'buy' or 'sell' recommendation. The presence of numerous warrants and convertible preferred stock with blocker provisions introduces a complex capital structure and potential future dilution, which warrants a 'hold' stance until further operational updates or financial results are available to assess the company's fundamental performance and strategic direction.

Keywords

PharmaCyte Biotech, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Convertible Preferred Stock, Biotech, SEC Filing, Institutional Ownership, Dilution